Download Supplementary Table 2

Supplementary Table 2. Cohort studies of cancers associated with biologic DMARD use in patients with rheumatoid arthritis.
Article
Country
Main
Comparator
Outcome
Finding
Newuser
design
Morgan
2014S53
Solomon
2014S54
UK
Etanercept
Traditional DMARDs
No elevated risk of malignancy was found.
No
USA
Methotrexate
Yes
Sweden
Traditional DMARDs
Invasive melanoma
No
Yes
USA
Adalimumab
Etanercept, Infliximab
Fatal infections
(secondary)
Reduced cancer risk was observed among TNF
inhibitors and Traditional bDMARDs compared to
methotrexate.
50% increase risk of invasive melanoma was
observed.
Rates of fatal infections were similar among three
agents.
No
Raascho
u 2013S55
Thyagara
jan
2012S16
VenturaRíos
2012S18
Mercer
2012S56
Koike
2011S24
Slimani
2011S57
Dixon
2010S58
Strangfel
d 2010S59
Askling
2009S60
Pallavicin
i 2010S61
Wolfe
2007S62
Setoguch
i 2006S63
Geborek
2005S64
TNF inhibitors,
Traditional DMARDs,
Rituximab, Abatacept
TNF inhibitors
Long-term safety
including cancer
Cancer
Activecompar
ator
design
Yes
Yes
Yes
Mexico
Biological DMARDs
Traditional DMARDs
Safety including
infections
Higher infection risk than traditional bDMARDs.
No
Yes
UK
TNF inhibitors
Traditional DMARDs
No
Tocilizumab
-
Yes
No
France
Rituximab
-
Yes
No
UK
Traditional DMARDs
with prior malignancy
Traditional DMARDs
with prior malignancy
Traditional DMARDs
Cancer
No
Yes
Recurrent cancer
Yes
Yes
Sweeden
TNF inhibitors with
prior malignancy
Biological DMARDs
with prior malignancy
TNF inhibitors
Risk was not elevated compared to Traditional
bDMARDs.
Most frequent serious adverse events were
infections.
Overall cancer rate was comparable to historical
Traditional DMARD cohorts.
Among the selected population studied, no increased
risk was observed.
No increased risk was observed.
No
Japan
Keratinocyte skin
cancer
Safety including
infections
Cancer
Cancer
No elevated risk of malignancy was found.
Yes
Yes
Italy
TNF inhibitors
-
Cancer
No
No
USA
TNF inhibitors
Lymphoma
No
Yes
USA,
Canada
Sweeden
TNF inhibitors
Traditional DMARDs
or none
Methotrexate
No elevated risk for overall cancer was found,
however, lymphoma risk was elevated.
No increased risk was observed.
Malignancies
No elevated risk of malignancy was found.
Yes
Yes
TNF inhibitors
Traditional DMARDs
Malignancies
No elevated risk for overall cancer was found,
however, lymphoma risk was elevated.
No
Yes
Germany
-1-
References:
S16.Thyagarajan, V., Norman, H., Alexander, K. A., Napalkov, P. & Enger, C. Risk of mortality, fatal infection, and fatal malignancy related to use of
anti-tumor necrosis factor-alpha biologics by rheumatoid arthritis patients. Semin Arthritis Rheum 42, 223–233 (2012).
S18.Ventura-Rios, L. et al. Patient survival and safety with biologic therapy. Results of the Mexican National Registry Biobadamex 1.0. Reumatol Clin 8, 189–
194 (2012).
S24.Koike, T. et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 70, 2148–
2151 (2011).
S53.Morgan, C. L. et al. Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and
survival using prospective, observational data. Rheumatology (Oxford) 53, 186–194 (2014).
S54.Solomon, D. H. et al. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin
Arthritis Rheum 43, 489–497 (2014).
S55.Raaschou, P., Simard, J. F., Holmqvist, M. & Askling, J. Rheumatoid arthritis, anti-tumour necrosis factor therapy, and risk of malignant melanoma:
nationwide population based prospective cohort study from Sweden. BMJ 346, (2013).
S56.Mercer, L. K. et al. The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results
from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 71, 869–874 (2012).
S57.Slimani, S., Lukas, C., Combe, B. & Morel, J. Rituximab in rheumatoid arthritis and the risk of malignancies: report from a French cohort. Joint Bone Spine
78, 484–487 (2011).
S58.Dixon, W. G. et al. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior
malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 62, 755–763 (2010).
S59.Strangfeld, A. et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics
register RABBIT. Arthritis Res Ther 12, (2010).
S60.Askling, J. et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time
since start of treatment? Arthritis Rheum 60, 3180–3189 (2009).
S61.Pallavicini, F. B. et al. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. Autoimmun Rev 9, 175–180
(2010).
S62.Wolfe, F. & Michaud, K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562
patients during 89,710 person-years of observation. Arthritis Rheum 56, 1433–1439 (2007).
S63.Setoguchi, S. et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54, 2757–2764 (2006).
S64.Geborek, P. et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an
increased risk of lymphomas. Ann Rheum Dis 64, (2005).
-2-